We'll be there for you!
For our next participation at the ASCCO congress, we will be there to present you:
Latest results from work with numerous partners on the usefulness of targeting hPG80 for multiple cancers
Our DxPG80 IVD test for the detection and assay of hPG80 in blood plasma, which began commercialization and clinical operations in late 2019.
And finally, this seminal scientific publication published in the scientific press on the overexpression of hPG80 (circulating extracellular progastrin) in multiple cancers.
We are pleased to share this good news with you, the fruit of the many partnerships we have entered into together.